Pathstone Holdings
FOLD

Pathstone Holdings’s Amicus Therapeutics FOLD Stock Holding History

Pathstone Holdings’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Buy
102,796
+2,686
+3% +$38.5K 0.01% 1201
2025
Q4 		$1.43M Sell
100,110
-1,688
-2% -$16.6K 0.01% 1211
2025
Q3 		$802K Buy
101,798
+1,688
+2% +$12K ﹤0.01% 1543
2025
Q2 		$574K Sell
100,110
-108
-0.1% -$697 ﹤0.01% 1660
2025
Q1 		$818K Sell
100,218
-1,533
-2% -$14.2K ﹤0.01% 1481
2024
Q4 		$958K Sell
101,751
-5,225
-5% -$54.3K ﹤0.01% 1385
2024
Q3 		$1.14M Sell
106,976
-1,391
-1% -$15.1K 0.01% 1293
2024
Q2 		$1.08M Buy
108,367
+2,394
+2% +$24.6K ﹤0.01% 1292
2024
Q1 		$1.25M Buy
105,973
+617
+0.6% +$7.89K 0.01% 1145
2023
Q4 		$1.5M Buy
+105,356
New +$1.2M 0.01% 855

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Pathstone Holdings's FOLD Position: Q1 2026 in Review

Pathstone Holdings increased its Amicus Therapeutics (FOLD) stake by 2.7% in Q1 2026, buying an estimated $38.5K and bringing the position to 102,796 shares worth $1.49M. The position accounts for 0.01% of the portfolio, ranked #1201.

Pathstone Holdings first reported a position in FOLD in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.5M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Pathstone Holdings held 102,796 shares of Amicus Therapeutics worth $1.49M as of Q1 2026.
  • Pathstone Holdings bought 2,686 Amicus Therapeutics shares in Q1 2026, an estimated $38.5K.
  • Amicus Therapeutics made up 0.01% of Pathstone Holdings's portfolio in Q1 2026, its #1201 holding.
  • Pathstone Holdings first reported a position in Amicus Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Pathstone Holdings's Amicus Therapeutics position peaked at $1.5M in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.